Nifty
Sensex
:
:
14238.90
48347.59
-133.00 (-0.93%)
-530.95 (-1.09%)

Pharmaceuticals & Drugs - Global

Rating :
78/99

BSE: 524804 | NSE: AUROPHARMA

998.60
25-Jan-2021
  • Open
  • High
  • Low
  • Previous Close
  •  935.00
  •  1023.70
  •  932.00
  •  923.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  14754225
  •  145631.59
  •  1023.70
  •  288.85

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 58,476.67
  • 18.62
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 61,231.65
  • 0.30%
  • 3.19

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.94%
  • 0.98%
  • 8.78%
  • FII
  • DII
  • Others
  • 24.99%
  • 12.58%
  • 0.73%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.09
  • 10.86
  • 11.95

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.58
  • 8.82
  • 5.22

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.58
  • 7.06
  • 5.55

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.29
  • 16.88
  • 15.42

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.21
  • 3.67
  • 2.77

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.90
  • 11.32
  • 10.13

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
6,483.44
5,600.47
15.77%
5,924.78
5,444.60
8.82%
6,158.43
5,292.20
16.37%
5,895.00
5,269.67
11.87%
Expenses
5,050.63
4,460.25
13.24%
4,667.43
4,298.20
8.59%
4,842.21
4,234.73
14.35%
4,686.96
4,183.29
12.04%
EBITDA
1,432.81
1,140.22
25.66%
1,257.35
1,146.40
9.68%
1,316.22
1,057.47
24.47%
1,208.04
1,086.38
11.20%
EBIDTM
22.10%
20.36%
21.22%
21.06%
21.37%
19.98%
20.49%
20.62%
Other Income
53.75
20.62
160.67%
115.59
15.78
632.51%
32.59
32.27
0.99%
30.93
63.85
-51.56%
Interest
15.71
40.94
-61.63%
21.07
49.89
-57.77%
31.83
50.08
-36.44%
37.11
47.65
-22.12%
Depreciation
257.34
243.31
5.77%
255.52
240.86
6.09%
232.41
186.62
24.54%
250.13
163.12
53.34%
PBT
1,213.51
863.83
40.48%
1,096.35
858.73
27.67%
1,096.82
816.86
34.27%
938.81
914.42
2.67%
Tax
387.33
224.37
72.63%
303.67
227.76
33.33%
228.52
231.12
-1.12%
232.86
204.78
13.71%
PAT
826.18
639.46
29.20%
792.68
630.97
25.63%
868.30
585.74
48.24%
705.95
709.64
-0.52%
PATM
12.74%
11.42%
13.38%
11.59%
14.10%
11.07%
11.98%
13.47%
EPS
13.76
10.92
26.01%
13.32
10.85
22.76%
14.50
9.99
45.15%
12.04
12.16
-0.99%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
24,461.65
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
4,627.40
4,381.48
Net Sales Growth
13.21%
18.07%
18.83%
10.42%
8.08%
13.81%
49.64%
38.33%
26.54%
5.61%
 
Cost Of Goods Sold
9,991.49
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
2,303.99
1,963.83
Gross Profit
14,470.16
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
2,323.41
2,417.65
GP Margin
59.15%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
53.38%
50.21%
55.18%
Total Expenditure
19,247.23
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
4,066.10
3,418.22
Power & Fuel Cost
-
587.68
556.79
470.95
437.14
419.26
359.60
349.84
324.72
232.36
208.26
% Of Sales
-
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
5.02%
4.75%
Employee Cost
-
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
535.69
425.07
% Of Sales
-
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
11.58%
9.70%
Manufacturing Exp.
-
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
623.04
543.16
511.60
% Of Sales
-
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
10.64%
11.74%
11.68%
General & Admin Exp.
-
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
283.49
197.83
130.74
120.34
% Of Sales
-
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
2.83%
2.75%
Selling & Distn. Exp.
-
1,524.75
1,125.76
1,025.85
848.43
901.87
878.98
359.60
305.98
208.20
141.59
% Of Sales
-
6.60%
5.75%
6.23%
5.69%
6.54%
7.25%
4.44%
5.23%
4.50%
3.23%
Miscellaneous Exp.
-
529.75
413.24
298.75
203.97
187.92
227.09
123.20
149.49
111.96
141.59
% Of Sales
-
2.29%
2.11%
1.81%
1.37%
1.36%
1.87%
1.52%
2.55%
2.42%
1.08%
EBITDA
5,214.42
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
561.30
963.26
EBITDA Margin
21.32%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
12.13%
21.98%
Other Income
232.86
191.87
155.32
101.98
115.89
203.80
96.71
21.56
28.54
24.70
71.41
Interest
105.72
305.13
262.60
77.72
66.72
256.70
159.87
310.16
266.64
277.24
64.65
Depreciation
995.40
966.71
667.95
557.97
427.63
392.37
332.61
312.53
248.74
200.53
171.50
PBT
4,345.49
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
108.23
798.52
Tax
1,152.38
913.52
726.85
818.27
759.65
720.71
596.59
363.45
82.71
-88.81
225.12
Tax Rate
26.52%
24.31%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
41.70%
28.56%
PAT
3,193.11
2,846.14
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
-123.50
563.45
PAT before Minority Interest
3,194.57
2,844.69
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
-124.14
563.06
Minority Interest
1.46
1.45
0.23
0.26
0.47
1.50
4.51
3.78
2.46
0.64
0.39
PAT Margin
13.05%
12.32%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
-2.67%
12.86%
PAT Growth
24.45%
20.50%
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
-
-
 
EPS
54.50
48.58
40.31
41.30
39.20
34.54
26.89
20.02
5.02
-2.11
9.62

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
16,810.38
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
2,339.65
2,444.83
Share Capital
58.59
58.59
58.59
58.59
58.52
29.20
29.15
29.12
29.11
29.11
Total Reserves
16,751.79
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
2,310.54
2,415.72
Non-Current Liabilities
565.88
358.13
594.11
102.07
583.85
1,591.60
1,493.91
1,225.26
967.29
645.49
Secured Loans
0.00
48.88
451.20
177.59
380.10
773.54
1,101.31
1,084.11
862.08
449.74
Unsecured Loans
0.00
131.07
0.00
3.81
362.71
587.93
178.05
64.15
102.55
73.61
Long Term Provisions
74.71
46.54
55.86
39.13
23.36
24.35
9.18
9.00
4.24
3.09
Current Liabilities
11,386.75
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
2,915.05
2,768.49
Trade Payables
2,545.01
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
963.75
660.14
776.35
Other Current Liabilities
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
387.68
150.87
580.34
699.09
Short Term Borrowings
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
1,608.21
1,234.73
Short Term Provisions
544.88
384.67
294.23
261.36
132.93
218.24
126.60
80.09
66.36
58.32
Total Liabilities
28,763.15
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
Net Block
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
2,194.65
1,738.60
Gross Block
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
3,086.25
2,438.00
Accumulated Depreciation
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
891.60
699.40
Non Current Assets
12,350.65
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
2,968.16
2,546.75
Capital Work in Progress
1,985.94
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
167.82
515.74
582.86
Non Current Investment
554.69
360.20
311.52
245.85
122.94
0.14
19.76
22.24
19.86
38.49
Long Term Loans & Adv.
376.94
396.64
261.91
256.48
236.56
455.27
789.04
237.82
108.12
110.77
Other Non Current Assets
36.61
38.62
86.93
81.29
32.24
30.25
18.40
18.66
0.12
1.47
Current Assets
16,412.50
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
3,264.04
3,321.18
Current Investments
0.02
0.02
0.02
0.02
0.02
19.65
0.03
0.04
18.68
0.04
Inventories
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
1,545.56
1,455.27
Sundry Debtors
4,315.15
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
1,239.96
1,230.98
Cash & Bank
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
178.58
208.45
70.86
186.72
Other Current Assets
1,555.31
1,919.82
1,223.32
1,084.72
831.25
659.57
448.46
407.69
388.98
448.17
Short Term Loans & Adv.
1,065.96
795.90
753.96
512.09
366.88
387.90
237.22
207.51
216.67
358.87
Net Current Assets
5,025.75
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
705.92
348.99
552.69
Total Assets
28,763.15
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
646.28
274.87
326.25
335.11
PBT
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
108.23
798.52
Adjustment
1,091.17
813.95
535.02
408.92
487.50
406.28
515.12
441.54
387.22
197.72
Changes in Working Capital
276.87
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
-421.56
-128.34
-469.45
Cash after chg. in Working capital
5,111.08
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
990.23
394.09
367.11
526.79
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-729.80
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
-119.22
-40.86
-191.68
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
-563.16
-599.07
Net Fixed Assets
-606.64
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
-376.05
-396.28
Net Investments
-180.64
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
-135.92
-122.17
Others
-780.36
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
-513.08
57.10
-51.19
-80.62
Cash from Financing Activity
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
108.09
118.85
406.98
Net Cash Inflow / Outflow
866.46
667.44
892.08
-423.72
339.99
-67.95
-54.82
136.62
-118.06
143.02
Opening Cash & Equivalents
1,875.58
1,209.94
318.03
743.49
403.81
148.02
202.73
65.64
183.71
44.72
Closing Cash & Equivalent
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10
148.02
202.73
65.64
183.71

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
286.92
237.08
199.36
159.96
124.50
88.29
64.33
44.74
40.19
41.99
ROA
10.34%
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
-2.05%
10.57%
ROE
18.53%
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
-5.19%
26.35%
ROCE
18.80%
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
1.25%
19.29%
Fixed Asset Turnover
4.12
4.36
2.44
2.96
2.79
2.55
2.08
1.75
1.71
1.85
Receivable days
29.85
29.56
64.66
89.16
106.53
91.84
93.55
86.28
95.44
89.07
Inventory Days
57.72
59.64
112.70
101.43
100.27
88.91
94.82
105.51
115.91
104.17
Payable days
52.98
58.56
67.77
75.73
81.50
67.49
71.06
57.79
64.70
70.79
Cash Conversion Cycle
34.59
30.63
109.58
114.86
125.30
113.25
117.31
134.00
146.65
122.45
Total Debt/Equity
0.33
0.50
0.41
0.36
0.69
0.86
1.01
1.32
1.32
0.99
Interest Cover
13.32
12.76
42.66
46.80
11.69
14.56
5.94
2.40
0.23
13.19

News Update:


  • Aurobindo Pharma gets nod for promotion of manufacturing critical bulk drugs
    23rd Jan 2021, 10:05 AM

    The approval has also been given to Aurobindo Pharma (through Qule Pharma) for setting up plant for production of Erythromycin Thiocyanate

    Read More
  • Aurobindo Pharma enters into exclusive license agreement with COVAXX
    24th Dec 2020, 08:55 AM

    COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate

    Read More
  • Aurobindo Pharma gets USFDA’s nod for Dexmedetomidine HCL in 0.9% Sodium Chloride Injection
    9th Dec 2020, 10:20 AM

    The product will be launched in January 2021

    Read More
  • Aurobindo Pharma’s arms ink pact with affiliate of New Mountain Capital LLC, NY, Jarrow Formulas Inc
    1st Dec 2020, 09:31 AM

    The agreement is for dispose of Natrol LLC, USA, including its business assets as a going concern with related assets, liabilities, products, brands and employees

    Read More
  • Aurobindo Pharma gets nod to transfer business undertaking of Auronext Pharma
    12th Nov 2020, 09:37 AM

    The Board of Directors of the company at its meeting held on November 11, 2020, has, inter alia, considered and approved the same

    Read More
  • Aurobindo Pharma - Quarterly Results
    11th Nov 2020, 17:58 PM

    Read More
  • Aurobindo Pharma completes acquisition of MViyeS Pharma Ventures
    9th Nov 2020, 09:03 AM

    Now, both Eugia Pharma Specialities and MViyeS Pharma Ventures have become 100% subsidiaries of the Company

    Read More
  • Aurobindo Pharma signs definitive agreement to sell Natrol to New Mountain Capital
    26th Oct 2020, 11:56 AM

    Subject to customary closing conditions and regulatory approvals, the transaction is expected to close by January 2021

    Read More
  • Aurobindo Pharma gets USFDA’s approval for Acetaminophen Injection
    22nd Oct 2020, 12:45 PM

    Acetaminophen Injection is indicated for the treatment of mild to moderate pain in adult and pediatric patients 2 years and older

    Read More
  • Aurobindo Pharma’s arm receives warning letter from USFDA for New Jersey facility
    22nd Oct 2020, 11:17 AM

    The company believes that the existing business from this facility will not be impacted

    Read More
  • Aurobindo Pharma to acquire entire stake in MViyeS
    19th Oct 2020, 11:59 AM

    MViyeS is holding 32.18% shareholding in Eugia Pharma Specialities, a joint venture company in which the Company is holding 67.82%

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.